|
|
Medtronic Plc (NYSE: MDT) |
|
Price: $82.6000
$-0.09 
-0.109%
|
| Day's High:
| $82.905
| Week Perf:
| -0.36 %
|
| Day's Low: |
$ 82.28 |
30 Day Perf: |
-10.09 % |
| Volume (M): |
516 |
52 Wk High: |
$ 96.25 |
| Volume (M$): |
$ 42,659 |
52 Wk Avg: |
$85.62 |
| Open: |
$83.20 |
52 Wk Low: |
$75.96 |
|
|
| Market Capitalization (Millions $) |
106,240 |
| Shares
Outstanding (Millions) |
1,286 |
| Employees |
100,000 |
| Revenues (TTM) (Millions $) |
33,199 |
| Net Income (TTM) (Millions $) |
4,290 |
| Cash Flow (TTM) (Millions $) |
-383 |
| Capital Exp. (TTM) (Millions $) |
1,826 |
Medtronic Plc
Medtronic Plc is a leading global medical technology company that specializes in the development and manufacturing of medical devices and therapies aimed at treating a variety of chronic diseases. Established in 1949, Medtronic originally focused on cardiac devices and has since significantly expanded its portfolio to address numerous health issues across different medical fields.
Core Areas of Focus:
1. Cardiovascular Solutions: Medtronic is a pioneer in cardiac devices, producing products such as pacemakers, implantable cardioverter-defibrillators (ICDs), and stents. These devices are integral in treating heart diseases and managing arrhythmias.
2. Diabetes Management: The company offers a comprehensive range of products for diabetes management, including insulin pumps and continuous glucose monitoring systems designed to help patients manage their condition effectively.
3. Neuroscience: Medtronic develops various solutions for neurological disorders, including spinal cord stimulators for chronic pain management and deep brain stimulation devices for conditions such as Parkinson's disease.
4. Surgical Innovations: The companys surgical products include minimally invasive surgical instruments and robotic-assisted surgery systems, which enhance surgical precision and improve patient outcomes.
5. Gastrointestinal and Urological Solutions: Medtronic provides products that address gastrointestinal issues, such as feeding tubes and devices for bariatric surgery, as well as solutions for urological conditions.
Global Reach and Market Presence:
Medtronic operates in over 150 countries and has a strong market presence, holding leadership positions across nearly all major markets in which it competes. The companys extensive distribution network and broad product offerings enable it to deliver comprehensive healthcare solutions to a diverse patient population.
Commitment to Innovation:
Innovation is at the heart of Medtronics operations. The company invests significantly in research and development to enhance existing therapies and develop novel treatments. Collaborations with healthcare providers, technology companies, and academic institutions are part of its strategy to foster innovation and improve patient outcomes.
Corporate Responsibility and Ethics:
Medtronic is dedicated to corporate responsibility, focusing on ethical practices, sustainability, and community engagement. The company emphasizes its commitment to patient safety, product quality, and complying with regulatory requirements throughout its operations.
Recent Developments:
As of 2023, Medtronic continues to advance its digital health initiatives, integrating data analytics and artificial intelligence into its products to optimize patient care and improve management of chronic conditions. The company is also actively involved in initiatives aimed at enhancing healthcare access and affordability globally.
By maintaining its focus on innovative medical technologies and solutions, Medtronic strives to improve the quality of life for patients worldwide, adhering to its mission of restoring health and extending lives.
Company Address: Building Two, Parkmore Business Park West Galway 0
Company Phone Number: 438-1700 Stock Exchange / Ticker: NYSE MDT
|
|
|
Customers Net Income fell by |
MDT's Customers Net Profit Margin fell to |
-18.38 % |
1.46 %
|
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Stocks on the Move
Published Fri, Jul 19 2024 7:22 PM UTC
In the dynamic world of healthcare and medical technology, Medtronic Plc has been seeking to maintain its competitive edge. However, recent market performance indicates that the company has faced some hurdles, as its shares have trailed the overall market by 16.9% year to date. This article will delve into a variety of recent events surrounding Medtronic, including new techn...
|
| Medtronic Plc
Medtronic Plc (NYSE: MDT) is a global leader in healthcare technology that specializes in medical equipment and supplies. The company recently reported its financial results for the most recent fiscal period, which showed a revenue elevation of 0.527%. However, despite this increase in revenue, there was a significant income contraction of -44.28% compared to the same quarter a year ago.
In terms of specific numbers, Medtronic's revenue for the period was $8.59 billion, with earnings per share (EPS) at $0.49. While the company experienced a rise in top-line revenue, it fell below the average 7.28% increase seen by its contemporaries in the Medical Equipment & Supplies sector during the fourth quarter of 2023. When compared to the prior quarter, Medtronic's profit plummeted by -50.07% from $0.99 per share, while revenue grew by 6.181% from $8.09 billion.
|
| Stock Offering
Published Wed, May 29 2024 9:10 PM UTC
Medtronic plc Prices $3.0 Billion Senior Notes Offering, Boosting Financial Flexibility
DUBLIN, May 29, 2024 - Medtronic plc (NYSE: MDT) announced today that its subsidiary, Medtronic, Inc., has priced an offering of $3.0 billion in senior notes due in 2029. The offering consists of 3.650% senior notes, which will be used for general corporate purposes, including potenti...
|
| Medtronic Plc
Medtronic Plc, a global leader in healthcare technology, recently reported its third-quarter results for 2024. The company experienced a revenue growth of 4.685% to $8.09 billion compared to $7.73 billion in the same reporting season the previous year. This represents a solid performance, although it falls short of the 8.27% top-line improvement reported by its contemporaries in the Medical Equipment & Supplies sector.
In terms of earnings per share (EPS), Medtronic Plc saw an increase of 7.61% to $0.99 from $0.92 in the prior year reporting season. The company's bottom-line also showed improvement, with net earnings of $1,337.000 million in the third quarter of 2024, an 8.79% increase from $1,229.000 million reported in the same period a year ago.
|
| Products & Services
Published Mon, Jan 8 2024 5:38 PM UTC
FDA Approves Medtronic s Advanced Percept RC Neurostimulator with Exclusive BrainSense Technology: Revolutionizing Deep Brain StimulationIn a breakthrough development, the FDA has granted approval to Medtronic for its latest innovation - the Percept RC neurostimulator. Esteemed as the first and only deep brain stimulation system with sensing, directionality, and advanced pro...
|
| Per Share |
Current |
| Earnings (TTM) |
3.29 $ |
| Revenues (TTM) |
25.81 $
|
| Cash Flow (TTM) |
- |
| Cash |
6.16 $
|
| Book Value |
38.57 $
|
| Dividend (TTM) |
2.77 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
3.29 $
|
| Revenues (TTM) |
25.81 $ |
| Cash Flow (TTM) |
- |
| Cash |
6.16 $
|
| Book Value |
38.57 $ |
| Dividend (TTM) |
2.77 $ |
|
|
| |
| Reportable net sales |
|
 99.61 % |
of total Revenue |
| Cardiovascular |
|
36.63 % |
of total Revenue |
| Cardiovascular Cardiac Rhythm Heart Failure |
|
18.63 % |
of total Revenue |
| Cardiovascular Structural Heart Aortic |
|
10.54 % |
of total Revenue |
| Cardiovascular Coronary Peripheral Vascular |
|
7.45 % |
of total Revenue |
| Neuroscience |
|
29.64 % |
of total Revenue |
| Neuroscience Cranial Spinal Technologies |
|
15.07 % |
of total Revenue |
| Neuroscience Specialty Therapies |
|
8.83 % |
of total Revenue |
| Neuroscience Neuromodulation |
|
5.74 % |
of total Revenue |
| Medical Surgical |
|
24.99 % |
of total Revenue |
| Medical Surgical Surgical Endoscopy |
|
19.25 % |
of total Revenue |
| Medical Surgical Acute Care Monitoring |
|
5.74 % |
of total Revenue |
| Diabetes |
|
8.37 % |
of total Revenue |
| Other segment |
|
0.39 % |
of total Revenue |
| U S |
|
51.1 % |
of total Revenue |
| International |
|
48.9 % |
of total Revenue |
| Reportable net sales U S |
|
50.93 % |
of total Revenue |
| Reportable net sales International |
|
48.7 % |
of total Revenue |
| Cardiovascular U S |
|
16.94 % |
of total Revenue |
| Cardiovascular International |
|
19.68 % |
of total Revenue |
| Neuroscience U S |
|
20.37 % |
of total Revenue |
| Neuroscience International |
|
9.27 % |
of total Revenue |
| Medical Surgical U S |
|
10.77 % |
of total Revenue |
| Medical Surgical International |
|
14.23 % |
of total Revenue |
| Diabetes U S |
|
2.85 % |
of total Revenue |
| Diabetes International |
|
5.51 % |
of total Revenue |
| Other U S |
|
0.18 % |
of total Revenue |
| Other International |
|
0.21 % |
of total Revenue |
| Ireland |
|
0.34 % |
of total Revenue |
| Total other countries excluding Ireland |
|
99.66 % |
of total Revenue |
| United States |
|
51.1 % |
of total Revenue |
| Rest of world |
|
48.56 % |
of total Revenue |
|
|
3.77% 